Prognostic impact of repeat sentinel lymph node biopsy in patients with ipsilateral breast tumour recurrence

I. G. M. Poodt*, G. Vugts, R. J. Schipper, R. M. H. Roumen, H. J. T. Rutten, A. J. G. Maaskant-Braat, A. C. Voogd, G. A. P. Nieuwenhuijzen, Sentinel Node Recurrent Breast

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

77 Downloads (Pure)

Abstract

Background: Ipsilateral breast tumour recurrence (IBTR) has an unfavourable prognosis, with a significant subsequent risk of distant recurrence. Repeat sentinel lymph node biopsy (rSLNB) has recently been demonstrated to be technically feasible and useful in tailoring adjuvant treatment plans in patients with IBTR. The prognostic impact of rSLNB in patients with IBTR remains unclear. This study analysed the risk of distant recurrence after IBTR, and evaluated the prognostic impact of rSLNB and other patient and tumour characteristics on distant recurrence-free survival.

Methods: Data were obtained from the SNARB (Sentinel Node and Recurrent Breast Cancer) study. Cox proportional hazards analyses were performed to assess the prognostic effect of tumour, patient and treatment factors on distant recurrence-free survival.

Results: Of the 515 included patients, 230 (44.7 per cent) had a tumour-negative rSLNB and 46 (8.9 per cent) a tumour-positive rSLNB. In 239 patients (46.4 per cent) the rSLNB procedure was unsuccessful. After a median follow-up of 5.1 years, 115 patients (22.3 per cent) had developed a recurrence. The overall 5-year distant recurrence-free survival rate was 84.2 (95 per cent c.i. 80.7 to 87.7) per cent. An interval of less than 2 years between primary breast cancer treatment and ipsilateral recurrence (P = 0.018), triple-negative IBTR (P = 0.045) and absence of adjuvant chemotherapy after IBTR (P = 0.010) were independently associated with poor distant recurrence-free survival. The association between the outcome of rSLNB and distant recurrence-free survival was not statistically significant (P = 0.682).

Conclusion: The outcome of rSLNB is not an important prognostic factor for distant recurrence, and its value as a staging tool in patients with IBTR seems disputable.

Original languageEnglish
Pages (from-to)574-585
Number of pages12
JournalBritish Journal of Surgery
Volume106
Issue number5
DOIs
Publication statusPublished - Apr 2019

Keywords

  • SURGICAL ADJUVANT BREAST
  • CONSERVATION THERAPY
  • CONSERVING THERAPY
  • LOCAL RECURRENCE
  • LOCOREGIONAL RECURRENCES
  • CANCER
  • SURGERY
  • METAANALYSIS
  • PATTERNS
  • FAILURE

Fingerprint

Dive into the research topics of 'Prognostic impact of repeat sentinel lymph node biopsy in patients with ipsilateral breast tumour recurrence'. Together they form a unique fingerprint.

Cite this